Low diagnosis of onychomycosis may inhibit adequate treatment
Dermatophytic onychomycosis (DO) is a form of chronic fungal infection of the nails caused by dermatophytes, a type of fungi…
Read More…
Focus:
-
![BioNTech acquires Neon]()
BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share...
Read More...
-
![]()
Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule
Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule.
Read More...
-
![]()
How HMI create leaner, more flexible pharmaceutical print processes
Pharmaceuticals use some the most advanced technology in the packaging industry, setting trends that regularly...
Read More...
-
![]()
NICE cancer guidance: good news for Ibrance and Lynparza
The UK’s pricing regulator NICE decides whether new therapies are sufficiently cost-effective for NHS use....
Read More...
-
![Clovis Rubraca FDA fast track]()
FDA grants Clovis’ Rubraca fast track designation for prostate cancer
Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration...
Read More...
-
![Japan ViiV Dovato HIV]()
Japan approves ViiV’s two drug regimen Dovato for HIV
ViiV Healthcare’s human immunodeficiency virus (HIV) drug Dovato (dolutegravir 50mg/lamivudine 300mg) has been approved by...
Read More...
-
![ageing drug development]()
What does ‘ageing’ mean when it comes to drug development?
The WHO is considering a new framework, which proposes the classification of aging as a...
Read More...
-
![]()
AI and automation: Transforming product and safety vigilance data into smart, personalized insights
Patients are using powerful drugs and medical devices, which are extremely efficient at enhancing and...
Read More...
-
![MorphoSys Incyte B cell deal]()
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US...
Read More...
